Recent discussions among medical societies suggest renaming the condition known as Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change reflects the understanding that this condition is not merely a gynecological issue; it involves the entire metabolic system.
According to the World Health Organization (WHO), nearly 13% of women of reproductive age suffer from this syndrome. The new terminology aims to highlight that cycle irregularities often serve as early warning signs for insulin resistance and type 2 diabetes.
Why the New Name Makes Sense
The diagnosis of PMOS continues to rely on irregular menstrual cycles, elevated testosterone levels, or multiple follicles in the ovaries. Proponents argue that the term PMOS better encapsulates the hormonal and metabolic causes than PCOS does.
However, not everyone is in favor of this change. Critics caution that it could lead to confusion in diagnosis and potential issues with insurance coverage if the established term PCOS is completely replaced.
Weight Management: The Struggles of Affected Patients
For many women, losing weight is the most challenging aspect of treatment. For example, Megan Tjelle, who began her journey in October 2022, lost an initial 26 kg through lifestyle changes and an additional 23 kg using the medication Wegovy.
Dietary supplements are also coming into the spotlight. A study published in the journal Nutrients in 2026 examined Myo-Inositol (MI) and found that it increases ovulation rates by 2.75 times and live birth rates by 2.3 times. Furthermore, it produces fewer gastrointestinal side effects compared to the commonly used medication Metformin.
New Studies Highlight Myo-Inositol’s Benefits
The recent findings in Nutrients emphasize that Myo-Inositol increases live birth rates while causing significantly fewer side effects than Metformin. Interested individuals can learn how to effectively include Myo-Inositol in their treatments through our complimentary report. Request the Report Now
However, researchers remain cautious, noting that the existing studies are still insufficient. Myo-Inositol is recommended only as a supplement to basic therapy, not as a standalone solution.
Annual Check-Ups for Affected Women
Given the long-term health risks associated with PMOS, new preventative standards are needed. The UK’s National Institute for Health and Care Excellence (NICE) has drafted a proposal for women with PMOS to receive annual examinations. These assessments will include cardiovascular parameters, diabetes tests, BMI monitoring, and psychological aspects.
In the UK, 3-4 million women are affected, particularly those of Black, Asian, or mixed ethnic backgrounds. NICE also recommends annual bone density measurements for women over 50 with relevant indications, as a 2023 study in the British Medical Journal demonstrated that regular checks reduce fracture risks by up to 25%.
AI’s Role in Early Detection
In addition to clinical studies, digital solutions are gaining traction. Researcher Karen Kumar developed an AI platform for early detection of PMOS after personally receiving the diagnosis in 2023. The system cross-references symptoms like skin changes or cycle irregularities with lab data to facilitate earlier diagnoses using predictive analytics, paving the way for personalized treatments.
If you’re struggling to conceive due to PCOS, Myo-Inositol offers natural support, contributing to a 275% higher ovulation rate according to recent studies. Find out all the facts and application tips in our free report. Secure Your Free Report Now
